Thomas Thorpe
Afton Scientific
CEO
Mr. Thorpe has over 40 years of professional experience in pharmaceutical operations, entrepreneurial initiatives and corporate finance/investment banking. He is currently the CEO of Afton Scientific Corporation, a cGMP contract manufacturer of sterile drugs and products for use in new drug development and FDA approved commercial drug production.
He is a founding board member and currently a member of the Executive Committee of the Pharmaceutical and Bio-Pharmaceutical Outsourcing Association (BPOA). In this capacity, he participated on the Industry-FDA negotiation team for the 2017 and 2022 Generic Drug User Fee Act (GDUFA). He has served as Board Chair of the Virginia Biotechnology Association (Virginia Bio) a statewide non-profit organization that promotes the scientific and economic impact of the life sciences industry in the Commonwealth of Virginia.
Mr. Thorpe is former board member of Contraline LLC, a biotechnology company developing a novel male contraceptive.
He holds a BS degree in Chemical Engineering from the University of Connecticut and an MBA from the University of Virginia.
He is a founding board member and currently a member of the Executive Committee of the Pharmaceutical and Bio-Pharmaceutical Outsourcing Association (BPOA). In this capacity, he participated on the Industry-FDA negotiation team for the 2017 and 2022 Generic Drug User Fee Act (GDUFA). He has served as Board Chair of the Virginia Biotechnology Association (Virginia Bio) a statewide non-profit organization that promotes the scientific and economic impact of the life sciences industry in the Commonwealth of Virginia.
Mr. Thorpe is former board member of Contraline LLC, a biotechnology company developing a novel male contraceptive.
He holds a BS degree in Chemical Engineering from the University of Connecticut and an MBA from the University of Virginia.